Article Text

Download PDFPDF
Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node–Positive Cervical Cancer Treated With Definitive Chemoradiotherapy
  1. Dong Hyun Kim, MD*,
  2. Won Taek Kim, MD, PhD*,
  3. Jin Suk Bae, MD*,
  4. Yong Kan Ki, MD, PhD*,
  5. Dahl Park, PhD*,
  6. Dong Soo Suh, MD, PhD,
  7. Ki Hyung Kim, MD, PhD,
  8. Joo Hye Lee, MD,
  9. Ja Young Lee, MD,
  10. Ho Sang Jeon, PhD and
  11. Ji Ho Nam, MD
  1. *Departments of Radiation Oncology and
  2. Departments of Obstetrics and Gynecology, Biomedical Research Institute, Pusan National University Hospital and Pusan National University School of Medicine, Pusan National University, Busan; and
  3. Departments of Department of Radiation Oncology, Yangsan Pusan National University Hospital, Yangsan, Korea.
  1. Address correspondence and reprint requests to Won Taek Kim, MD, PhD, Department of Radiation Oncology, Pusan National University School of Medicine, 1-10, Ami-dong, Seo-gu, Busan, Korea. E-mail: rokwt@hanmail.net.

Abstract

Objectives This study aimed to identify prognostic factors for para-aortic lymph node (PALN) recurrence and their effect on survival outcomes in patients with pelvic node–positive squamous cell carcinoma (SCC) of the cervix treated with definitive concurrent chemoradiotherapy (CCRT).

Materials and Methods Of the 116 patients with biopsy-proven SCC of the uterine cervix who underwent primary CCRT from 2007 to 2012, 48 patients with pelvic LN metastasis detected by [18F]-fluorodeoxyglucose positron emission tomography (FDG PET) were retrospectively analyzed. Patients with evidence of para-aortic lymphadenopathy were excluded. The whole pelvis was the standard irradiation field for all patients. The associations of age, stage, serum SCC antigen (SCC-Ag) level, maximum standardized uptake value (SUVmax), hemoglobin level, overall treatment time, adjuvant chemotherapy, and pelvic LN status with PALN recurrence and survival outcomes were evaluated.

Results At a median follow-up of 34.0 months (range, 8–73 months), 10 (20.8%) patients had developed PALN recurrences. The relationship between pelvic LN FDG uptake and PALN recurrence was evaluated by the cutoff value (SUVmax = 3.85) determined by receiver operating characteristic curve analysis. The independent risk factors for PALN recurrence were FDG-avid pelvic LN (SUVPLN) greater than 3.85 (hazard ratio, 13.12; P = 0.025) and posttreatment SCC-Ag level greater than 2.0 (ng/mL) (hazard ratio, 20.69; P = 0.019). Patients with an SUVPLN greater than 3.85 were found to have significantly worse 5-year distant metastasis-free (51.0% vs 79.0%, P = 0.016) and progression-free survival (38.7% vs 67.3%, P = 0.011) than those with an SUVPLN less than or equal to 3.85.

Conclusions SUVPLN is a statistically significant prognostic factor of PALN recurrence and survival after definitive CCRT for pelvic node–positive SCC of the uterine cervix.

  • Para-aortic lymph node
  • Squamous cell carcinoma
  • Uterine cervix
  • 18F-fluorodeoxyglucose positron emission tomography (FDG PET)
  • Concurrent chemoradiotherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.